Baseline CYP450 Drug Metabolism
Placeholder: liver enzymes clear the drug at a steady, predictable rate.
- ~57: Liver CYP450 enzymes (placeholder gene family count)
- ~50%: Drugs metabolized via CYP3A4 (placeholder share of market drugs)
- 8–24h: Typical half-life (placeholder, drug dependent)
- 1.0×: Baseline blood level (placeholder therapeutic midpoint)
What CYP450 enzymes do
Placeholder: enzymes oxidize drug molecules so the body can excrete them efficiently.
Why steady clearance matters
Placeholder: constant clearance keeps blood levels inside the safe therapeutic window.
Cannabinoids Bind and Block the Enzyme
Placeholder: CBD competitively inhibits CYP3A4, CYP2C9, and CYP2C19.
- 3 enzymes: CBD inhibits (placeholder CYP3A4/2C9/2C19)
- Hours: Inhibition onset (placeholder after dosing)
- Yes: Dose-dependent effect (placeholder higher dose = more block)
- Competitive: Mechanism (placeholder active-site binding)
Competitive inhibition basics
Placeholder: cannabinoid molecules occupy the enzyme active site, blocking substrate.
Which enzymes are affected
Placeholder: CYP3A4, CYP2C9, CYP2C19 are the most cannabinoid-sensitive pathways.
Medication Metabolism Slows Down
Placeholder: with the enzyme blocked, drug clearance rate drops sharply.
- Up to 50%+: Clearance reduction (placeholder at high CBD dose)
- Extended: Half-life (placeholder, roughly doubles)
- Same day: Onset of slowdown (placeholder co-administration)
- Reversible: Reversibility (placeholder once CBD clears)
Clearance rate vs. dose
Placeholder: higher CBD dose produces proportionally slower drug clearance.
Backing up in the bloodstream
Placeholder: unmetabolized drug molecules accumulate faster than they are removed.
Drug Concentration Climbs Above Range
Placeholder: blood level rises past the therapeutic band as clearance lags.
- 1.3–2×: Level increase (placeholder typical elevation)
- 0.8–1.2×: Therapeutic band (placeholder normal range)
- Days: Time to peak (placeholder steady-state shift)
- Recommended: Monitoring (placeholder blood level checks)
Crossing the therapeutic band
Placeholder: level rise pushes concentration outside the safe target range.
Narrow vs wide index drugs
Placeholder: narrow-index drugs tolerate far less deviation before harm.
Outcome — Elevated Toxicity Risk
Placeholder: excess drug level raises risk of adverse effects or toxicity.
- Warfarin: Example narrow-index drugs (placeholder, anti-epileptics)
- High: Risk at high dose+narrow (placeholder combined scenario)
- Low: Risk at low dose+wide (placeholder combined scenario)
- Consult MD: Clinical guidance (placeholder before combining)
Why narrow-index drugs matter most
Placeholder: small level changes cause large safety margin shifts for these drugs.
Managing the interaction
Placeholder: dose adjustment or level monitoring can reduce toxicity risk.
Placeholder key insight: always check CYP450 interactions before combining cannabis with prescriptions.